GMAB vs. VRTX

Last updated Apr 1, 2026

Compare and contrast key facts about Genmab A/S (GMAB) and Vertex Pharmaceuticals Incorporated (VRTX).

Performance

GMAB vs. VRTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Genmab A/S (GMAB) and Vertex Pharmaceuticals Incorporated (VRTX). The values are adjusted to include any dividend payments, if applicable.

GMAB vs. VRTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
GMAB Genmab A/S	-12.89%	47.58%	-34.45%	-24.87%	7.13%	-2.71%	82.09%	35.54%	-0.61%	-0.04%
VRTX Vertex Pharmaceuticals Incorporated	-1.50%	12.58%	-1.03%	40.90%	31.50%	-7.08%	7.94%	32.13%	10.58%	103.42%

Fundamentals

Market Cap GMAB : $18.05B VRTX : $114.36B
EPS GMAB : $4.58 VRTX : $15.35
PE Ratio GMAB : 5.86 VRTX : 29.09
PEG Ratio GMAB : 0.18 VRTX : 2.42
PS Ratio GMAB : 1.19 VRTX : 9.58
PB Ratio GMAB : 0.49 VRTX : 6.13
Total Revenue (TTM) GMAB : $14.32B VRTX : $12.00B
Gross Profit (TTM) GMAB : $13.35B VRTX : $10.35B
EBITDA (TTM) GMAB : $5.15B VRTX : $4.74B

Returns By Period

In the year-to-date period, GMAB achieves a -12.89% return, which is significantly lower than VRTX's -1.50% return. Over the past 10 years, GMAB has underperformed VRTX with an annualized return of 6.68%, while VRTX has yielded a comparatively higher 18.89% annualized return.

GMAB

• 1D: 3.87%
• 1M: -8.87%
• YTD: -12.89%
• 6M: -12.52%
• 1Y: 37.03%
• 3Y*: -10.77%
• 5Y*: -4.02%
• 10Y*: 6.68%

VRTX

• 1D: 0.76%
• 1M: -10.12%
• YTD: -1.50%
• 6M: 14.02%
• 1Y: -7.90%
• 3Y*: 12.33%
• 5Y*: 15.95%
• 10Y*: 18.89%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GMAB vs. VRTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GMAB

GMAB Risk / Return Rank: 70
GMAB Sharpe Ratio Rank: 76
GMAB Sortino Ratio Rank: 70
GMAB Omega Ratio Rank: 67
GMAB Calmar Ratio Rank: 67
GMAB Martin Ratio Rank: 70

VRTX

VRTX Risk / Return Rank: 31
VRTX Sharpe Ratio Rank: 32
VRTX Sortino Ratio Rank: 29
VRTX Omega Ratio Rank: 29
VRTX Calmar Ratio Rank: 32
VRTX Martin Ratio Rank: 31

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GMAB vs. VRTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Genmab A/S (GMAB) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GMAB	VRTX	Difference
Sharpe ratio Return per unit of total volatility	1.07	-0.22	+1.29
Sortino ratio Return per unit of downside risk	1.55	-0.05	+1.60
Omega ratio Gain probability vs. loss probability	1.19	0.99	+0.20
Calmar ratio Return relative to maximum drawdown	1.20	-0.33	+1.54
Martin ratio Return relative to average drawdown	3.42	-0.65	+4.08
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GMAB vs. VRTX - Sharpe Ratio Comparison

The current GMAB Sharpe Ratio is 1.07, which is higher than the VRTX Sharpe Ratio of -0.22. The chart below compares the historical Sharpe Ratios of GMAB and VRTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	GMAB	VRTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.07	-0.22	+1.29
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.12	0.56	-0.68
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.19	0.57	-0.38
Sharpe Ratio (All Time) Calculated using the full available price history	0.28	0.26	+0.03

Correlation

The correlation between GMAB and VRTX is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

GMAB vs. VRTX - Dividend Comparison

Neither GMAB nor VRTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

GMAB vs. VRTX - Drawdown Comparison

The maximum GMAB drawdown since its inception was -84.20%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for GMAB and VRTX.

Drawdown Indicators

	GMAB	VRTX	Difference
Max Drawdown Largest peak-to-trough decline	-84.20%	-91.77%	+7.57%
Max Drawdown (1Y) Largest decline over 1 year	-28.98%	-28.06%	-0.92%
Max Drawdown (5Y) Largest decline over 5 years	-63.10%	-29.07%	-34.03%
Max Drawdown (10Y) Largest decline over 10 years	-63.10%	-41.60%	-21.50%
Current Drawdown Current decline from peak	-44.93%	-13.59%	-31.34%
Average Drawdown Average peak-to-trough decline	-30.93%	-37.81%	+6.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	10.17%	14.33%	-4.16%

Volatility

GMAB vs. VRTX - Volatility Comparison

The current volatility for Genmab A/S (GMAB) is 10.95%, while Vertex Pharmaceuticals Incorporated (VRTX) has a volatility of 11.93%. This indicates that GMAB experiences smaller price fluctuations and is considered to be less risky than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GMAB	VRTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.95%	11.93%	-0.98%
Volatility (6M) Calculated over the trailing 6-month period	24.93%	21.67%	+3.26%
Volatility (1Y) Calculated over the trailing 1-year period	34.94%	35.83%	-0.89%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.00%	28.77%	+4.23%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	35.13%	33.24%	+1.89%

Financials

GMAB vs. VRTX - Profitability Comparison

The chart below illustrates the profitability comparison between Genmab A/S and Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

GMAB - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Genmab A/S reported a gross profit of 6.21B and revenue of 6.72B. Therefore, the gross margin over that period was 92.3%.

VRTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.72B and revenue of 3.19B. Therefore, the gross margin over that period was 85.4%.

GMAB - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Genmab A/S reported an operating income of 1.54B and revenue of 6.72B, resulting in an operating margin of 23.0%.

VRTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported an operating income of 1.26B and revenue of 3.19B, resulting in an operating margin of 39.6%.

GMAB - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Genmab A/S reported a net income of 196.98M and revenue of 6.72B, resulting in a net margin of 2.9%.

VRTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Vertex Pharmaceuticals Incorporated reported a net income of 1.19B and revenue of 3.19B, resulting in a net margin of 37.3%.